TLDR, $SAVA shows a ton of potential. Calls are fairly cheap and momentum has been good. If you have the liquidity to afford it, 2025 calls and beyond will absolutely PRINT

---

Doubling down on SAVA calls. After a panic crash on Monday it’s bouncing back nicely, earnings report in a couple of weeks, release of trial data sometime around q3 or q4, and another substantial release for Jan 2025 roughly. I’ve been watching these guys for a few years and they seem to be at the forefront of innovative Alzheimer’s research and treatment. Price was inflated at one point since until they receive approval and have all the data they need they’re running on investors; however, that approval will come and the price will skyrocket.

---